A pioneering clinical trial has demonstrated that personalized IVF treatments based on endometrial immune profiling can significantly increase live birth rates (LBR) compared to conventional care. The large-scale, randomized study, led by MatriceLab, found that patients who received tailored care informed by the UTIMPRO endometrial immune test had a live birth rate of 41.4%, in stark contrast to the 29.7% rate observed in the control group receiving standard IVF protocols.
The findings, published in Frontiers in Immunology, mark a significant step forward in the field of reproductive medicine, illustrating the potential of precision medicine in improving fertility outcomes. The study showed particularly promising results for women with morphologically suboptimal embryos (39.6% LBR versus 21.2% for the control group) and those with a history of two or more failed transfers (41% LBR versus 25.5%).
The authors of the study suggest that incorporating endometrial immune profiling into routine assisted reproductive technology (ART) practices could become a game-changer for IVF success. “This research provides compelling evidence that endometrial immune health is a critical factor in the success of ART, potentially transforming clinical approaches to fertility care,” the paper concluded.
Infertility is a widespread issue, affecting approximately 17.5% of people globally, according to the World Health Organization. Despite advances in ART, the live birth rate per initial IVF cycle remains low, particularly for women over 35, where success rates decrease rapidly with age.
The trial examined the endometrial immune profiles of 484 patients, revealing that 78% (378 patients) had dysregulated immune profiles. These patients were randomly assigned to receive either personalized immune-based care or conventional treatment. Those in the immune profiling group showed significantly higher success rates, further confirming the critical role of uterine immunity in IVF outcomes.
Dr. Nathalie Lédée, co-founder and CEO of MatriceLab, highlighted the trial’s importance, stating, “For years, the impact of uterine immunity on IVF success was debated, with skepticism surrounding immune testing. This trial provides clear evidence that identifying and addressing endometrial immune imbalances can improve live birth rates.”
Dr. Laura Prat-Ellenberg, senior author and Head of Reproductive Medicine at L’hôpital Pierre Rouquès – Les Bluets, added, “While embryo quality has long been the focus, this study underscores the significance of the endometrial immune environment. Immune profiling and targeted treatment not only enhance success rates but also reshape our understanding of why some embryos implant successfully while others fail.”
This landmark study offers new hope for couples struggling with infertility and could pave the way for more personalized, effective IVF treatments in the future.
Related topics:
New Survey: 45% of Women with Eating Disorders Face Infertility
Breaking the Silence: The Untold Struggles of Infertility and Its Stigmatization
